Theravance Biopharma, Inc. $TBPH Shares Acquired by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 14.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 983,615 shares of the biopharmaceutical company's stock after purchasing an additional 124,658 shares during the quarter. Dimensional Fund Advisors LP owned about 1.91% of Theravance Biopharma worth $15,960,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of TBPH. Swiss National Bank purchased a new stake in shares of Theravance Biopharma during the first quarter worth approximately $1,219,000. Precision Wealth Strategies LLC acquired a new position in Theravance Biopharma during the 1st quarter worth approximately $1,019,000. Financiere des Professionnels Fonds d investissement inc. acquired a new position in Theravance Biopharma during the first quarter worth $268,000. Allspring Global Investments Holdings LLC purchased a new position in Theravance Biopharma in the first quarter worth $171,000. Finally, Principal Financial Group Inc. purchased a new position in Theravance Biopharma in the first quarter worth $848,000. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Theravance Biopharma

In other Theravance Biopharma news, major shareholder Eli Samaha sold 273,871 shares of the firm's stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $17.23, for a total value of $4,718,797.33. Following the sale, the insider owned 9,237,279 shares in the company, valued at approximately $159,158,317.17. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Rhonda Farnum sold 13,314 shares of Theravance Biopharma stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $16.39, for a total value of $218,216.46. Following the sale, the senior vice president directly owned 232,457 shares in the company, valued at approximately $3,809,970.23. This trade represents a 5.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 350,011 shares of company stock valued at $6,008,309 over the last three months. 7.65% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on TBPH shares. Weiss Ratings upgraded shares of Theravance Biopharma from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday. Wall Street Zen lowered shares of Theravance Biopharma from a "buy" rating to a "hold" rating in a research report on Saturday, May 16th. JonesTrading cut Theravance Biopharma from a "buy" rating to a "hold" rating in a report on Monday, June 29th. HC Wainwright lowered Theravance Biopharma from a "buy" rating to a "neutral" rating and increased their target price for the stock from $15.00 to $17.00 in a research report on Tuesday, July 7th. Finally, Zacks Research cut Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a report on Monday, June 8th. Eight equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, Theravance Biopharma presently has an average rating of "Hold" and a consensus price target of $19.40.

Theravance Biopharma Stock Up 0.1%

Shares of NASDAQ TBPH opened at $16.93 on Friday. Theravance Biopharma, Inc. has a fifty-two week low of $11.20 and a fifty-two week high of $21.03. The business has a 50 day moving average price of $16.77 and a two-hundred day moving average price of $16.93. The firm has a market cap of $872.74 million, a PE ratio of 7.70 and a beta of 0.19.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The business had revenue of $17.70 million during the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. On average, analysts anticipate that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current year.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.

Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source